Adverse effects of GLP-1 analogues: A systematic review
DOI:
https://doi.org/10.33448/rsd-v14i1.47981Keywords:
GLP-1 analogs; Adverse effects; Treatment.Abstract
The increasing use of glucagon-like peptide-1 receptor analogs (GLP-1RAs) in the treatment of obesity and associated comorbidities has generated interest in evaluating their adverse effects, particularly gastrointestinal ones. In this context, the present study aims to analyze the adverse effects associated with the use of GLP-1 receptor analogs (GLP-1RAs), based on a systematic review of clinical studies. This was a systematic literature review, with data search conducted in the PUBMED, LILACS, and SCIELO databases. Initially, 1,696 articles were identified in the initial search, and after evaluating titles and abstracts, followed by the selection and detailed analysis of the articles, 11 studies were deemed eligible to be included in this systematic review. The total sample comprised approximately 23,596 individuals. There was a predominance of female participants in most of the studies, and the age range of the participants varied on average from 14.6 to 69 years. The most common and frequent adverse effects were, for the most part, mild to moderate, such as gastrointestinal symptoms, including nausea, vomiting, diarrhea, constipation, among others. However, some studies also identified severe adverse effects in certain patients, highlighting the need for clinical monitoring during treatment. In conclusion, although GLP-1 analogs offer significant clinical benefits, continuous patient monitoring is essential to manage adverse effects, ensuring safety and long-term adherence to treatment.
References
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024). Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: A randomised clinical trial. Diabetologia, 67(3), 470-482.
D'Marco, L., et al. (2021). SGLT2i e GLP-1RA em doenças cardiometabólicas e renais: Do controle glicêmico à inflamação e senescência do tecido adiposo. Journal of Diabetes Research, 2021(1), 1-17.
Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503-515.
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 23(3), 754-762.
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024). Gastrointestinal effects of GLP-1 receptor agonists: Mechanisms, management, and future directions. The Lancet Gastroenterology & Hepatology, 9(10), 957-964.
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.; NN8022-4180 Trial Investigators. (2020). A randomized, controlled trial of liraglutide for adolescents with obesity. The New England Journal of Medicine, 382(22), 2117-2128.
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., Jensen, T. J., Liisberg, K., Lindegaard, M. L., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., ... Shah, S. J.; STEP-HFpEF DM Trial Committees and Investigators. (2024). Semaglutide in patients with obesity-related heart failure and type 2 diabetes. The New England Journal of Medicine, 390(15), 1394-1407.
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 7(10), 776-785.
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., et al.; SELECT Trial Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221-2232.
Moraes, A. L. S. M. de., Vilela, B. S. ., Souza, B. C. ., Falleiros , I. de F. I. ., Pereira , I. L. ., & Ribeiro , J. S. O. . (2022). Adverse effects of semaglutide compared to liraglutide: an integrative literature review. Research, Society and Development, 11(10), e579111033181.
Nahra, R., Wang, T., Gadde, K. M., et al. (2021). Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: A 54-week randomized phase 2b study. Diabetes Care, 44(6), 1433-1442.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLOS Medicine, 18(3), e1003583.
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., et al. (2021). A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes, Obesity and Metabolism, 23(2), 363-373.
Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., et al.; STEP 8 Investigators. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138-150.
Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003). Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument. ANZ Journal of Surgery, 73(9), 712-716.
Vilela, B. S., Vilela, L. S., Ribeiro, J. S. O., Monteiro, I. de L. P., & Nobre, S. O. (2024). Corticosteroid use and the risk of glaucoma: A systematic review. Research, Society and Development, 13(12), e49131247453.
Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., Leonard, S., Mugler, K., Bakizada, Z., & Tronieri, J. S. (2019). Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: A randomized controlled trial. Obesity (Silver Spring), 27(1), 75-86.
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., & König, M.; GZGI Investigators. (2023). Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. The New England Journal of Medicine, 389(10), 877-888.
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al.; STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002.
Williams, D. M., Staff, M., Bain, S. C., & Min, T. (2022). Glucagon-like peptide-1 receptor analogues for the treatment of obesity. Touch Reviews in Endocrinology, 18(1), 43.
Yanovski, S. Z., & Yanovski, J. A. (2021). Progress in pharmacotherapy for obesity. JAMA, 326(2), 129-130.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Bárbara Natália Corrêa dos Santos; Rogério Soares Castro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
